Integral Diagnostics Limited
ACN 130 832 816

T | +61 3 5339 0704
E | info@idxgroup.com.au

Level 2
288 Victoria Parade
East Melbourne VIC 3002

PO Box 551
East Melbourne VIC 8002

www.integraldiagnostics.com.au

Correction to Appendix 3Y – Andy Fay NED

4 November 2026, Melbourne

Integral Diagnostics Limited (ASX: IDX) has identified a typographical error in the Appendix 3Y lodged today on behalf of Mr Andrew Fay, Non-Executive Director.

IDX confirms that prior to the change in interest notified today, Mr Fay had the following interests in IDX shares:

Indirectly:	47,000 Ordinary Shares (Narelle Fay – Spouse)
	15,000 Ordinary Shares (Mr Andrew Fay + Mrs Narelle Fay <Andrew Fay Super>)
Directly:	23,000 Ordinary Shares

Mr Fay has indirectly acquired a further 60,000 Ordinary Shares (Narelle Fay – Spouse).

A corrected Appendix 3Y is attached.

For further details contact

Integral Diagnostics
John Merity
Company Secretary
Tel: +0418 817 255
Email: jmerity@idxgroup.com.au

Authorised for lodgement by the Company Secretary.

About IDX:

Integral Diagnostics (IDX) is a leading provider of medical imaging services across Australia and New Zealand. IDX employs some of Australasia's leading radiologists and diagnostic imaging specialists in a unique medical leadership model that ensures quality patient care, service and access. Good medicine is good business. For more information, please visit www.integraldiagnostics.com.au/.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Integral Diagnostics Limited
ABN	55 130 832 816

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Andrew Fay
Date of last notice	30 November 2023

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect	Indirect	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Narelle Fay (spouse)	Mr Andrew Fay + Mrs Narelle Fay <Andrew Fay Super > (trustee and beneficiary of trust)	Andrew Fay
Date of change	3 November 2026	N/A	N/A
No. of securities held prior to change	47,000 Ordinary Shares	15,000 Ordinary Shares	23,000 Ordinary Shares
Class	Ordinary Fully Paid	N/A	N/A
Number acquired	60,000	Nil	Nil
Number disposed	Nil	Nil	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	$1.7275 per share	N/A	N/A

+ See chapter 19 for defined terms.

No. of securities held after change	107,000 Ordinary Shares	15,000 Ordinary Shares	23,000 Ordinary Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On Market Trade	N/A	N/A

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.